| 4.39 -0.26 (-5.59%) | 11-09 11:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.62  |
1-year : | 6.9 |
| Resists | First : | 4.81 |
Second : | 5.9 |
| Pivot price | 4.38  |
|||
| Supports | First : | 3.04 |
Second : | 2.53 |
| MAs | MA(5) : | 4.59 |
MA(20) : | 4.15 |
| MA(100) : | 3.5 |
MA(250) : | 3.56 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 50.2 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 5.9 | Low : | 2.67 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRME ] has closed above bottom band by 48.4%. Bollinger Bands are 87.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.7 - 4.72 | 4.72 - 4.74 |
| Low: | 4.4 - 4.42 | 4.42 - 4.45 |
| Close: | 4.61 - 4.65 | 4.65 - 4.69 |
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Mon, 09 Nov 2026
A gene-editing company’s CEO will speak in London on Nov. 16. - Stock Titan
Fri, 06 Nov 2026
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Wed, 28 Oct 2026
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains? - Yahoo Finance
Sat, 17 Oct 2026
Prime Medicine, Inc. (PRME) - What Are Brokerages Thinking About This Stock? - MarketBeat
Mon, 12 Oct 2026
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Yahoo Finance
Tue, 06 Oct 2026
Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins - Timothy Sykes
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 181 (M) |
| Held by Insiders | 1.1225e+008 (%) |
| Held by Institutions | 20.2 (%) |
| Shares Short | 32,130 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8912e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 750.8 % |
| Return on Equity (ttm) | -46.6 % |
| Qtrly Rev. Growth | 4.07e+006 % |
| Gross Profit (p.s.) | 1.62 |
| Sales Per Share | -173.63 |
| EBITDA (p.s.) | -6.6107e+007 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -156 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 42.56 |
| Dividend | 0 |
| Forward Dividend | 3.287e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|